These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 3191211)
1. Adjuvant chemotherapy with and without radiotherapy in stage II breast cancer. Brufman G; Sulkes A; Biran S Biomed Pharmacother; 1988; 42(5):351-5. PubMed ID: 3191211 [TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732 [TBL] [Abstract][Full Text] [Related]
3. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202 [TBL] [Abstract][Full Text] [Related]
4. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen. Isaac N; Panzarella T; Lau A; Mayers C; Kirkbride P; Tannock IF; Vallis KA Cancer; 2002 Aug; 95(4):696-703. PubMed ID: 12209711 [TBL] [Abstract][Full Text] [Related]
5. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M; Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948 [TBL] [Abstract][Full Text] [Related]
6. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. Fisher B; Jeong JH; Anderson S; Wolmark N J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638 [TBL] [Abstract][Full Text] [Related]
7. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N; J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958 [TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983 [TBL] [Abstract][Full Text] [Related]
9. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma. Bellon JR; Shulman LN; Come SE; Li X; Gelman RS; Silver BJ; Harris JR; Recht A Cancer; 2004 Apr; 100(7):1358-64. PubMed ID: 15042668 [TBL] [Abstract][Full Text] [Related]
10. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L; J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies. Goldhirsch A; Gelber R NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016 [TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial. Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89. Ejlertsen B; Mouridsen HT; Jensen MB Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334 [TBL] [Abstract][Full Text] [Related]
14. Concurrent chemotherapy and radiation for breast conservation treatment of early-stage breast cancer. Markiewicz DA; Fox KR; Schultz DJ; Harris EE; Haas JA; Glick JH; Solin LJ Cancer J Sci Am; 1998; 4(3):185-93. PubMed ID: 9612601 [TBL] [Abstract][Full Text] [Related]
15. [Simultaneous radiochemotherapy in locoregional recurrent breast carcinoma after mastectomy. Results in patients with macroscopic residual tumor R2]. Renner H; van Kampen M Strahlenther Onkol; 1994 Aug; 170(8):441-52. PubMed ID: 8085210 [TBL] [Abstract][Full Text] [Related]
16. A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Arcangeli G; Pinnarò P; Rambone R; Giannarelli D; Benassi M Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):161-7. PubMed ID: 16226397 [TBL] [Abstract][Full Text] [Related]
17. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Gianni L; Baselga J; Eiermann W; Porta VG; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Cussac AL; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez JJ; Mansutti M; Valagussa P; Bonadonna G J Clin Oncol; 2009 May; 27(15):2474-81. PubMed ID: 19332727 [TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K; Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922 [TBL] [Abstract][Full Text] [Related]
19. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Beriwal S; Schwartz GF; Komarnicky L; Garcia-Young JA Breast J; 2006; 12(2):159-64. PubMed ID: 16509842 [TBL] [Abstract][Full Text] [Related]
20. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer. Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]